查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930165

全球脑膜炎双球菌疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Meningococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 请询问到货日

价格

脑膜炎双球菌疫苗市场成长驱动因子

受侵袭性脑膜炎双球菌疾病发生率上升、疫苗接种计画扩大以及疫苗技术持续创新等因素的推动，全球脑膜炎双球菌疫苗市场持续稳定成长。在2025年报告期内，市场规模达到106.1亿美元，反映出人们对预防由脑膜炎奈瑟菌引起的危及生命的感染的疫苗接种需求强劲。预计到2026年，市场规模将达到41.2亿美元，并在2034年进一步扩大至92.4亿美元，这主要得益于公众意识的提高、政府主导的疫苗接种策略以及多种血清群疫苗接种覆盖范围的扩大。

脑膜炎双球菌感染，包括脑膜炎和败血症等严重疾病，若不及时治疗，病情可能迅速恶化并危及生命。在已知的12个脑膜炎双球菌血清群中，A、B、C、W、X和Y这六个血清群是全球疫情的主要病原体。由于脑膜炎双球菌感染死亡率高，且可能引发脑损伤、听力丧失和截肢等长期併发症，因此接种疫苗仍然是最有效的预防措施，从而支撑了市场需求的持续增长。

市场概览及主要洞察

预计到2025年，北美将以13.36%的市场占有率引领脑膜炎球菌疫苗市场，这得益于其先进的医疗保健体系、强大的监测基础设施和完善的国家疫苗接种计划。 受疾病发病率上升和积极的疫苗接种政策推动，预计到2025年，该地区市场规模将达到22.1亿美元。美国在其中扮演着核心角色，这得益于报告病例的增加以及针对青少年、青年和高风险族群的疫苗产品持续获得批准。

亚太地区是成长最快的区域市场，这得益于人们对疾病的认识不断提高、世界卫生组织支持的疫苗接种计划以及区域製造商提供的高性价比疫苗。欧洲凭藉成功的国家疫苗接种计划和高疫苗接种率（尤其是在儿童群体中）保持着强劲的地位。

市场动态

市场驱动因素

全球细菌性脑膜炎发生率的上升是主要的成长因素。根据世界卫生组织（世卫组织）统计，六分之一的细菌性脑膜炎病例会导致死亡，五分之一的倖存者会留下永久性残疾。 光是美国在2023年就报告了438例脑膜炎球菌疾病病例，这是过去十年来的最高数字。这些数据凸显了广泛接种疫苗的迫切性，并支撑了全球市场需求。

市场限制因子

脑膜炎双球菌疫苗的高成本限制了其广泛应用，尤其是在中低收入国家。结合疫苗和多价疫苗需要复杂的生产流程和严格的冷链物流，从而推高了整体成本。私部门疫苗价格超过每剂170-230美元，可能会限制无保险族群获得疫苗的机会。

市场机会

政府主导的消除脑膜炎的努力带来了强劲的成长机会。诸如 "2030年消除脑膜炎" 倡议等国际计画正在推动高负担地区提高免疫接种覆盖率。世界卫生组织支持的经济实惠的多价疫苗的推出有助于提高疫苗可及性并实现疾病的长期减少。

市场挑战

对冷链的依赖以及储存基础设施不足仍然是重大挑战。由于冷藏设备故障和停电造成的疫苗浪费持续给公共卫生系统带来经济负担，并限制了资源匮乏地区疫苗的有效分发。

市场趋势

影响市场的关键趋势是五价（MenABCWY）疫苗的研发，该疫苗可预防五种最常见的致病血清群。这些疫苗简化了接种程序，降低了物流复杂性，并提高了覆盖率。近期五价疫苗获得监管部门批准，正在加速其在青少年和成人疫苗接种计划中的应用。

市场区隔分析

依技术分类

重组/结合/次单位疫苗细分市场占最大的市场占有率，这得益于其优异的免疫原性和持久的保护作用。 全液体单剂量结合疫苗等创新进一步巩固了这个市场。灭活疫苗在疫情爆发期间的大规模疫苗接种活动中继续发挥重要作用。

依类型

由于被纳入青少年常规免疫接种计划，MenACWY疫苗占了市场主导地位。虽然MenB疫苗的需求保持稳定，但由于MenABCWY疫苗覆盖范围更广且近期获得批准，预计其成长速度将更快。

依年龄组

儿科市场占主导地位，这主要得益于国家儿童免疫接种计划和婴幼儿疫苗使用范围的扩大。高风险族群疾病发生率的上升也推动了成人疫苗的需求。

依分销管道

政府供应商占最大占有率，他们利用批量采购和公共疫苗接种计划来扩大市场占有率。 医院和零售药局正在城市和半城市地区扩大疫苗的供应范围。

"全球脑膜炎双球菌疫苗市场（2025）" 报告对2025年、2026年和2034年的市场规模和价值进行了全面分析，涵盖疾病流行病学、市场动态、技术趋势、市场细分、区域展望、竞争格局和关键行业发展。该报告重点关注疫苗接种覆盖率、监管环境、研发进展以及塑造脑膜炎双球菌疾病预防未来的全球努力。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家的监管环境
  • 主要国家的疫苗接种覆盖率
  • 主要国家的政府脑膜炎疫苗接种计划
  • 脑膜炎双球菌疫苗的技术进步
  • 主要产业趋势：併购、商业合作等。

第五章：全球脑膜炎双球菌疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依技术分类
    • 重组/结合/次单位疫苗
    • 灭活​​疫苗
    • 其他
  • 市场分析、洞察与预测：依类型分类
    • MenACWY疫苗
    • MenB疫苗
    • MenABCWY疫苗
    • 其他
  • 市场分析、洞察与预测：依年龄组别分类
    • 儿科
    • 成人
  • 市场分析、洞察与预测：依销售管道分类
    • 医院与零售通路药房
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美脑膜炎双球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲脑膜炎双球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 美国王国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区脑膜炎双球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲脑膜炎双球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区美国

第十章：中东与非洲脑膜炎双球菌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
    • GSK plc
    • Sanofi
    • Merck &Co., Inc.
    • Serum Institute of India Pvt. Ltd.
    • Novartis AG
    • Walvax Biotechnology Co., Ltd.
    • Hualan Biological Vaccine Inc.
    • Bio Farma
    • BioNet-Asia.
Product Code: FBI113758

Growth Factors of meningococcal vaccines Market

The global meningococcal vaccines market is experiencing consistent expansion, supported by the rising incidence of invasive meningococcal diseases, expanding immunization programs, and continuous innovation in vaccine technology. As per the 2025 report year, the market size stood at USD 10.61 billion in 2025, reflecting the strong demand for preventive vaccination against life-threatening infections caused by Neisseria meningitidis. The market is projected to reach USD 4.12 billion in 2026 and further expand to USD 9.24 billion by 2034, driven by increased awareness, government-backed immunization strategies, and broader vaccine coverage against multiple serogroups.

Meningococcal disease includes severe conditions such as meningitis and septicemia, which progress rapidly and can be fatal if untreated. Among the 12 known serogroups of N. meningitidis, six-A, B, C, W, X, and Y-are responsible for the majority of global epidemics. Due to high mortality and long-term complications such as brain damage, hearing loss, and limb amputation, vaccination remains the most effective preventive strategy, fueling sustained market demand.

Market Overview and Key Insights

In 2025, North America dominated the meningococcal vaccines market with a 13.36% share, supported by advanced healthcare systems, strong surveillance infrastructure, and established national immunization schedules. The region recorded a market size of USD 2.21 billion in 2025, driven by rising disease incidence and proactive vaccination policies. The U.S. plays a central role due to increased reported cases and continuous product approvals aimed at adolescents, young adults, and high-risk populations.

Asia Pacific represents the fastest-growing regional market, supported by rising disease awareness, WHO-backed vaccination programs, and the availability of cost-effective vaccines from regional manufacturers. Europe maintains a strong position due to successful national immunization programs and high vaccine coverage rates, particularly among pediatric populations.

Market Dynamics

Market Drivers

The increasing global incidence of bacterial meningitis is a primary growth driver. According to the World Health Organization, 1 in 6 individuals with bacterial meningitis die, and 1 in 5 survivors experience permanent disabilities. In the U.S. alone, 438 meningococcal disease cases were reported in 2023, the highest number in a decade. Such data underscores the urgent need for widespread vaccination, boosting global market demand.

Market Restraints

The high cost of meningococcal vaccines limits adoption, particularly in low- and middle-income countries. Conjugate and multivalent vaccines require complex manufacturing processes and strict cold-chain logistics, increasing overall costs. Private-sector vaccine prices exceeding USD 170-230 per dose may restrict access for uninsured populations.

Market Opportunities

Government initiatives aimed at eliminating meningitis present strong growth opportunities. Global programs such as "Defeating Meningitis by 2030" are expanding immunization coverage in high-burden regions. WHO-supported rollout of affordable multivalent vaccines is increasing access and supporting long-term disease reduction.

Market Challenges

Cold-chain dependency and inadequate storage infrastructure remain major challenges. Vaccine wastage due to refrigeration failures and power disruptions continues to impose financial burdens on public health systems, limiting efficient vaccine distribution in resource-constrained regions.

Market Trends

A key trend shaping the market is the development of pentavalent (MenABCWY) vaccines, offering protection against the five most prevalent disease-causing serogroups. These vaccines simplify immunization schedules, reduce logistical complexity, and improve coverage efficiency. Recent regulatory approvals for pentavalent vaccines are accelerating adoption across adolescent and adult vaccination programs.

Segmentation Analysis

By Technology

The recombinant/conjugate/subunit vaccines segment held the largest market share, supported by superior immunogenicity and long-lasting protection. Innovations such as fully liquid, single-vial conjugate vaccines are further strengthening this segment. Inactivated vaccines maintain relevance in outbreak-driven mass immunization campaigns.

By Type

The MenACWY vaccines segment dominated due to inclusion in routine adolescent immunization schedules. MenB vaccines maintain steady demand, while MenABCWY vaccines are expected to grow at a faster pace due to broader serogroup coverage and recent approvals.

By Age Group

The pediatric segment leads the market, driven by national childhood vaccination programs and expanded indications for infants. Adult vaccination demand is also increasing due to rising disease incidence among high-risk populations.

By Distribution Channel

Government suppliers account for the largest share, leveraging bulk procurement and public immunization initiatives. Hospital and retail pharmacies are expanding access in urban and semi-urban areas.

Competitive Landscape

The meningococcal vaccines market is consolidated, with major players including GSK plc, Sanofi, and Pfizer Inc. holding a substantial share due to diversified vaccine portfolios and continuous R&D investments. Other significant contributors include Serum Institute of India, Walvax Biotechnology, Bio Farma, and Hualan Biological Vaccine, supporting global supply through affordable and region-specific vaccine solutions.

Report Coverage

The 2025 meningococcal vaccines market report delivers a comprehensive analysis of market size and value for 2025, 2026, and 2034, covering disease epidemiology, market dynamics, technology trends, segmentation, regional outlook, competitive landscape, and key industry developments. The report emphasizes vaccination coverage, regulatory progress, pipeline advancements, and global initiatives shaping the future of meningococcal disease prevention.

Conclusion

The global meningococcal vaccines market demonstrates a strong and structured growth outlook, underpinned by the rising incidence of invasive meningococcal diseases, expanding immunization coverage, and continuous advancements in multivalent vaccine development. With the market valued at USD 10.61 billion in 2025, projected to reach USD 4.12 billion in 2026, and expected to grow further to USD 9.24 billion by 2034, the market reflects sustained demand for effective preventive solutions against life-threatening meningococcal infections. North America's leadership, accounting for 13.36% market share in 2025, highlights the role of robust healthcare systems, surveillance programs, and routine vaccination schedules, while Asia Pacific's rapid growth underscores increasing access to affordable vaccines and global health initiatives. Despite challenges such as high vaccine costs, cold-chain dependency, and logistical constraints, strong government support, WHO-led programs, and the emergence of pentavalent vaccines covering major serogroups are reinforcing market fundamentals. Overall, the meningococcal vaccines market is positioned for steady long-term expansion, driven by public health priorities, technological innovation, and global efforts to reduce meningitis-related mortality and long-term complications.

Segmentation By Technology

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Others

By Type

  • MenACWY Vaccines
  • MenB Vaccines
  • MenABCWY Vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Meningitis, By Key Countries/ Regions
  • 4.4. Technological Advancements in Meningococcal Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. MenACWY Vaccines
    • 5.2.2. MenB Vaccines
    • 5.2.3. MenABCWY Vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. MenACWY Vaccines
    • 6.2.2. MenB Vaccines
    • 6.2.3. MenABCWY Vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. MenACWY Vaccines
    • 7.2.2. MenB Vaccines
    • 7.2.3. MenABCWY Vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. MenACWY Vaccines
    • 8.2.2. MenB Vaccines
    • 8.2.3. MenABCWY Vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. MenACWY Vaccines
    • 9.2.2. MenB Vaccines
    • 9.2.3. MenABCWY Vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. MenACWY Vaccines
    • 10.2.2. MenB Vaccines
    • 10.2.3. MenABCWY Vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Serum Institute of India Pvt. Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Novartis AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Hualan Biological Vaccine Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. BioNet-Asia.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 2: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 3: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 4: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 5: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 6: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 7: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 8: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 9: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 12: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 13: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 14: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 15: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 17: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 18: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 19: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 22: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 23: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 24: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 25: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 27: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 28: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 29: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Meningococcal Vaccines Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Meningococcal Vaccines Market Value Share (%), By Technology, 2025 & 2034
  • Figure 3: Global Meningococcal Vaccines Market Value Share (%), By Type, 2025 & 2034
  • Figure 4: Global Meningococcal Vaccines Market Value Share (%), By Age Group, 2025 & 2034
  • Figure 5: Global Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 6: Global Meningococcal Vaccines Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 8: North America Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 9: North America Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 10: North America Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 11: North America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 12: North America Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 13: North America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 14: North America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 15: North America Meningococcal Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Meningococcal Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 18: Europe Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 19: Europe Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 20: Europe Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 21: Europe Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 22: Europe Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 23: Europe Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 24: Europe Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 25: Europe Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 28: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 29: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 30: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 31: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 32: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 33: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 38: Latin America Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 39: Latin America Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 40: Latin America Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 41: Latin America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 43: Latin America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 45: Latin America Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 48: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 49: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 50: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 51: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 53: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 55: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Meningococcal Vaccines Market Share (%), By Company, 2025